CD274 and melanoma: From the early recognition of TILs as a surrogate of immune interactions in breast cancer (BC) and melanoma to the widespread use of PD-L1, these markers have shaped the landscape of decision making in Oncology and some of those have been incorporated as companion diagnostics by the regulatory authorities.